Comparing Outcomes Pre- and Post-Cancer Drugs Fund
In this paper we look at the 18 appraisals that had entered and exited the CDF between June 2016 and April 2022 to provide insights on what manufacturers can expect from the CDF and to understand whether the CDF is operating optimally to resolve genuine uncertainty in submissions.
Whitepaper
Oct 19, 2022
